Emphysema, pulmonary fibrosis and tissue repair
Quick answer
Chronic lung diseases such as emphysema and pulmonary fibrosis permanently damage alveoli and cut gas exchange. EHL Bio lists lung disease among conditions where stem cells hold potential, since MSCs are anti-inflammatory and anti-fibrotic. Human data, however, remain limited to small studies, so core treatment is still smoking cessation, inhaled bronchodilators, pulmonary rehabilitation and oxygen therapy where indicated.
Destroyed alveoli do not regrow in adults, so the realistic goal of any therapy is slowing decline, reducing exacerbations and improving quality of life — not restoring the lung to normal.
Most MSC lung studies use intravenous delivery, where many cells naturally lodge in the lung (first-pass effect), making it an accessible target — while also raising the need to watch for pulmonary vascular complications.
What is proven to cut mortality in COPD is smoking cessation and long-term oxygen in hypoxaemic patients, while pulmonary rehabilitation significantly improves walking distance and breathlessness.
If considering overseas cell therapy, request the research status, patient selection criteria and a follow-up plan using spirometry and the six-minute walk test as tangible endpoints.
No. Permanently damaged alveoli do not regenerate; the aim is slowing decline and easing symptoms.
Risk must be assessed individually; patients in respiratory failure are usually excluded from studies.
Fibrosis stiffens the lung and limits expansion; emphysema destroys alveolar walls and traps air. Treatment pathways differ.
Annual influenza, pneumococcal and COVID vaccination as advised genuinely reduce severe exacerbations.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Kidney, liver, heart, lung